EXHIBIT 99.1 Addex Reports Full Year 2022 Financial Results and Provides Corporate Update CHF 7.0M ($ 7.4M) of cash and cash equivalents at December 31, 2022 ADX71149 Phase 2 study in epilepsy cohort 1 completes part 1 – independent interim review committee (IRC) recommendation expected early Q2 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, March 30, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical- stage pharmaceutical company pioneering allosteric modulation-based ...

Addex Therapeutics Ltd (NASDAQ:ADXN) Q3 2022 Earnings Conference Call November 11, 2022 11:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and CEO Robert Lutjens - Head of Discovery, Biology Mikhail Kalinichev - Head of Translational Science Conference Call Participants Leonildo Delgado - Baader-Helvea Tim Dyer Hello, everyone. I'd like to thank you all for joining our Quarter Three 2022 Financial Results Conference Call. I'm here with Robert Lutjens, our Head of Discovery, Biology; and ...

Addex Therapeutics Ltd (NASDAQ:ADXN) Q2 2022 Earnings Conference Call August 18, 2022 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and CEO Roger Mills - Chief Medical Officer Robert Lütjens - Head of Discovery, Biology Conference Call Participants Raghuram Selvaraju - HC Wainwright Bob Pooler - valuationLAB AG Operator Good day and thank you for standing by. Welcome to the Addex Therapeutics to Announce Half Year 2022 Financial Results and provide Corporate Update Conference Call. ...

Addex Therapeutics Limited (NASDAQ:ADXN) Q4 2021 Earnings Conference Call March 10, 2022 10:00 AM ET Company Participants Tim Dyer - CEO Roger Mills - Chief Medical Officer Robert Lutjens - Head of Discovery Biology Conference Call Participants Raghuram Selvaraju - HC Wainwright Bob Pooler - valuationLAB AG Charles Duncan - Cantor Fitzgerald Tim Dyer Hello, everyone. I would like to thank you all for joining our 2020 full year financial results conference call. I am here with Roger Mills, our Chief Medical ...

财务数据（2021年） - 2021年12月31日现金及现金等价物为2050万瑞士法郎（2250万美元）[1] - 2021年收入较2020年减少70万瑞士法郎至320万瑞士法郎[7] - 2021年研发成本较2020年增加240万瑞士法郎至1280万瑞士法郎[8] - 2021年一般及行政费用稳定在约580万瑞士法郎[8] - 2021年净亏损为1540万瑞士法郎[9] - 2021年基本和稀释每股亏损降至0.45瑞士法郎[9] - 2021年12月31日现金及现金等价物较2020年增加180万瑞士法郎至2050万瑞士法郎[9] 临床试验数据报告时间 - 2022年第二季度将报告地拉格鲁用于眼睑痉挛的2a期数据[4] - 2022年第三季度将报告ADX71149用于癫痫的2a期数据[4] - 2023年上半年将报告地拉格鲁用于帕金森病相关异动症的2b/3期数据[4]